nach oben

Journal of Neuro-Oncology

Erschienen in:

29.05.2020 | Clinical Study

Long non-coding RNA GAS5, by up-regulating PRC2 and targeting the promoter methylation of miR-424, suppresses multiple malignant phenotypes of glioma

verfasst von: Chen Jin, Jie Zhao, Zhi-Ping Zhang, Ming Wu, Jian Li, Ge-Lei Xiao, Bo Liu, Yu-Xiang Liao, Jing-Ping Liu

Erschienen in: Journal of Neuro-Oncology | Ausgabe 3/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Malignant gliomas remain significant challenges in clinic and pose dismal prognosis on patients. In this study, we focused on growth arrest-specific 5 (GAS5), a tumor suppressive long non-coding RNA in glioma, explored its crosstalk with miR-424, and examined their biological functions in glioma.

Methods

Expressions of GAS5 and miR-424 were measured using qRT-PCR. The regulation of GAS5 on miR-424 expression was examined in GAS5-overexpressing glioma cells by combining methylation-specific PCR, western blotting, and RNA immunoprecipitation. Functional significance of GAS5 and miR-424 on in vitro cell proliferation, apoptosis, migration, invasion, and in vivo tumor growth was examined using colony formation, flow cytometry, wound healing, transwell assay, and the xenograft model, respectively. The potential targeting of AKT3 by miR-424 was investigated using luciferase reporter assay.

Results

GAS5 and miR-424 were significantly down-regulated in glioma cells. GAS5 directly interacted with enhancer of zeste homolog 2 (EZH2), stimulated the formation of polycomb repressive complex 2 (PRC2), reduced the levels of DNA methyltransferases (Dnmts), alleviated promoter methylation of miR-424, and promoted miR-424 expression. Functionally, GAS5, by up-regulating miR-424, inhibited cell proliferation, migration, and invasion, while increased apoptosis of glioma cells in vitro, and suppressed xenograft growth in vivo. miR-424 directly inhibited AKT3 and altered the expressions of AKT3 targets, cyclinD1, c-Myc, Bax, and Bcl-2, which might contribute to its tumor suppressive activities.

Conclusions

GAS5, by inhibiting methylation and boosting expression of miR-424, inhibits AKT3 signaling and suppresses multiple malignant phenotypes. Therefore, stimulating GAS5/miR-424 signaling may benefit the treatment of glioma.

Hadziahmetovic M, Shirai K, Chakravarti A (2011) Recent advancements in multimodality treatment of gliomas. Future Oncol 7:1169–1183. https://doi.org/10.2217/fon.11.102CrossRefPubMed

Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, Kleihues P (2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114:97–109. https://doi.org/10.1007/s00401-007-0243-4CrossRefPubMedPubMedCentral

Wahid F, Shehzad A, Khan T, Kim YY (2010) MicroRNAs: synthesis, mechanism, function, and recent clinical trials. Biochim Biophys Acta 1803:1231–1243. https://doi.org/10.1016/j.bbamcr.2010.06.013CrossRefPubMed

Kung JT, Colognori D, Lee JT (2013) Long noncoding RNAs: past, present, and future. Genetics 193:651–669. https://doi.org/10.1534/genetics.112.146704CrossRefPubMedPubMedCentral

Banelli B, Forlani A, Allemanni G, Morabito A, Pistillo MP, Romani M (2017) MicroRNA in glioblastoma: an overview. Int J Genomics 2017:7639084. https://doi.org/10.1155/2017/7639084CrossRefPubMedPubMedCentral

Kiang KM, Zhang XQ, Leung GK (2015) Long non-coding RNAs: the key players in glioma pathogenesis. Cancers (Basel) 7:1406–1424. https://doi.org/10.3390/cancers7030843CrossRef

Yang M, Bai HX, Yang L (2017) MicroRNA-21 expression in the prognosis of low-grade gliomas: data from the cancer genome atlas (TCGA) project. J Neurooncol 134:241–242. https://doi.org/10.1007/s11060-017-2500-2CrossRefPubMed

Xu J, Li Y, Wang F, Wang X, Cheng B, Ye F, Xie X, Zhou C, Lu W (2013) Suppressed miR-424 expression via upregulation of target gene Chk1 contributes to the progression of cervical cancer. Oncogene 32:976–987. https://doi.org/10.1038/onc.2012.121CrossRefPubMed

Long XH, Mao JH, Peng AF, Zhou Y, Huang SH, Liu ZL (2013) Tumor suppressive microRNA-424 inhibits osteosarcoma cell migration and invasion via targeting fatty acid synthase. Exp Ther Med 5:1048–1052. https://doi.org/10.3892/etm.2013.959CrossRefPubMedPubMedCentral

10.

Rodriguez-Barrueco R, Nekritz EA, Bertucci F, Yu J, Sanchez-Garcia F, Zeleke TZ, Gorbatenko A, Birnbaum D, Ezhkova E, Cordon-Cardo C, Finetti P, Llobet-Navas D, Silva JM (2017) miR-424(322)/503 is a breast cancer tumor suppressor whose loss promotes resistance to chemotherapy. Genes Dev 31:553–566. https://doi.org/10.1101/gad.292318.116CrossRefPubMedPubMedCentral

11.

Zhang M, Gao C, Yang Y, Li G, Dong J, Ai Y, Ma Q, Li W (2017) MiR-424 promotes non-small cell lung cancer progression and metastasis through regulating the tumor suppressor gene TNFAIP1. Cell Physiol Biochem 42:211–221. https://doi.org/10.1159/000477314CrossRefPubMed

12.

Wei S, Li Q, Li Z, Wang L, Zhang L, Xu Z (2016) miR-424-5p promotes proliferation of gastric cancer by targeting Smad3 through TGF-beta signaling pathway. Oncotarget 7:75185–75196. https://doi.org/10.18632/oncotarget.12092CrossRefPubMedPubMedCentral

13.

Jin C, Li M, Ouyang Y, Tan Z, Jiang Y (2017) MiR-424 functions as a tumor suppressor in glioma cells and is down-regulated by DNA methylation. J Neurooncol 133:247–255. https://doi.org/10.1007/s11060-017-2438-4CrossRefPubMed

14.

Hervouet E, Peixoto P, Delage-Mourroux R, Boyer-Guittaut M, Cartron PF (2018) Specific or not specific recruitment of DNMTs for DNA methylation, an epigenetic dilemma. Clin Epigenet 10:17. https://doi.org/10.1186/s13148-018-0450-yCrossRef

15.

Holoch D, Margueron R (2017) Mechanisms regulating PRC2 recruitment and enzymatic activity. Trends Biochem Sci 42:531–542. https://doi.org/10.1016/j.tibs.2017.04.003CrossRefPubMed

16.

Vire E, Brenner C, Deplus R, Blanchon L, Fraga M, Didelot C, Morey L, Van Eynde A, Bernard D, Vanderwinden JM, Bollen M, Esteller M, Di Croce L, de Launoit Y, Fuks F (2006) The Polycomb group protein EZH2 directly controls DNA methylation. Nature 439:871–874. https://doi.org/10.1038/nature04431CrossRefPubMed

17.

Ning X, Shi Z, Liu X, Zhang A, Han L, Jiang K, Kang C, Zhang Q (2015) DNMT1 and EZH2 mediated methylation silences the microRNA-200b/a/429 gene and promotes tumor progression. Cancer Lett 359:198–205. https://doi.org/10.1016/j.canlet.2015.01.005CrossRefPubMed

18.

Das PP, Hendrix DA, Apostolou E, Buchner AH, Canver MC, Beyaz S, Ljuboja D, Kuintzle R, Kim W, Karnik R, Shao Z, Xie H, Xu J, De Los AA, Zhang Y, Choe J, Jun DL, Shen X, Gregory RI, Daley GQ, Meissner A, Kellis M, Hochedlinger K, Kim J, Orkin SH (2015) PRC2 is required to maintain expression of the maternal Gtl2-Rian-Mirg locus by preventing de novo DNA methylation in mouse embryonic stem cells. Cell Rep 12:1456–1470. https://doi.org/10.1016/j.celrep.2015.07.053CrossRefPubMedPubMedCentral

19.

Zhao H, Yu H, Zheng J, Ning N, Tang F, Yang Y, Wang Y (2018) Lowly-expressed lncRNA GAS5 facilitates progression of ovarian cancer through targeting miR-196-5p and thereby regulating HOXA5. Gynecol Oncol. https://doi.org/10.1016/j.ygyno.2018.08.032CrossRefPubMedPubMedCentral

20.

Li S, Zhou J, Wang Z, Wang P, Gao X, Wang Y (2018) Long noncoding RNA GAS5 suppresses triple negative breast cancer progression through inhibition of proliferation and invasion by competitively binding miR-196a-5p. Biomed Pharmacother 104:451–457. https://doi.org/10.1016/j.biopha.2018.05.056CrossRefPubMed

21.

Yang W, Hong L, Xu X, Wang Q, Huang J, Jiang L (2017) LncRNA GAS5 suppresses the tumorigenesis of cervical cancer by downregulating miR-196a and miR-205. Tumour Biol 39:1010428317711315. https://doi.org/10.1177/1010428317711315CrossRefPubMed

22.

Liu Q, Yu W, Zhu S, Cheng K, Xu H, Lv Y, Long X, Ma L, Huang J, Sun S, Wang K (2018) Long noncoding RNA GAS5 regulates the proliferation, migration, and invasion of glioma cells by negatively regulating miR-18a-5p. J Cell Physiol. https://doi.org/10.1002/jcp.26889CrossRefPubMedPubMedCentral

23.

Zhao X, Liu Y, Zheng J, Liu X, Chen J, Liu L, Wang P, Xue Y (2017) GAS5 suppresses malignancy of human glioma stem cells via a miR-196a-5p/FOXO1 feedback loop. Biochim Biophys Acta 1864:1605–1617. https://doi.org/10.1016/j.bbamcr.2017.06.020CrossRef

24.

Zhao X, Wang P, Liu J, Zheng J, Liu Y, Chen J, Xue Y (2015) Gas5 exerts tumor-suppressive functions in human glioma cells by targeting miR-222. Mol Ther 23:1899–1911. https://doi.org/10.1038/mt.2015.170CrossRefPubMedPubMedCentral

25.

Sun D, Yu Z, Fang X, Liu M, Pu Y, Shao Q, Wang D, Zhao X, Huang A, Xiang Z, Zhao C, Franklin RJ, Cao L, He C (2017) LncRNA GAS5 inhibits microglial M2 polarization and exacerbates demyelination. EMBO Rep 18:1801–1816. https://doi.org/10.15252/embr.201643668CrossRefPubMedPubMedCentral

26.

Wang M, Guo C, Wang L, Luo G, Huang C, Li Y, Liu D, Zeng F, Jiang G, Xiao X (2018) Long noncoding RNA GAS5 promotes bladder cancer cells apoptosis through inhibiting EZH2 transcription. Cell Death Dis 9:238. https://doi.org/10.1038/s41419-018-0264-zCrossRefPubMedPubMedCentral

27.

Crowley LC, Christensen ME, Waterhouse NJ (2016) Measuring survival of adherent cells with the colony-forming assay. Cold Spring Harb Protoc. https://doi.org/10.1101/pdb.prot087171CrossRefPubMed

28.

Rieger AM, Nelson KL, Konowalchuk JD, Barreda DR (2011) Modified annexin V/propidium iodide apoptosis assay for accurate assessment of cell death. J Vis Exp. https://doi.org/10.3791/2597CrossRefPubMedPubMedCentral

29.

Liu C, Yang H, Xu Z, Li D, Zhou M, Xiao K, Shi Z, Zhu L, Yang L, Zhou R (2015) microRNA-548l is involved in the migration and invasion of non-small cell lung cancer by targeting the AKT1 signaling pathway. J Cancer Res Clin Oncol 141:431–441. https://doi.org/10.1007/s00432-014-1836-7CrossRefPubMed

30.

Li S, Chen T, Zhong Z, Wang Y, Li Y, Zhao X (2012) microRNA-155 silencing inhibits proliferation and migration and induces apoptosis by upregulating BACH1 in renal cancer cells. Mol Med Rep 5:949–954. https://doi.org/10.3892/mmr.2012.779CrossRefPubMedPubMedCentral

31.

Schmittgen TD, Livak KJ (2008) Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc 3:1101–1108CrossRefPubMed

32.

Mundi PS, Sachdev J, McCourt C, Kalinsky K (2016) AKT in cancer: new molecular insights and advances in drug development. Br J Clin Pharmacol 82:943–956. https://doi.org/10.1111/bcp.13021CrossRefPubMedPubMedCentral

33.

Turner KM, Sun Y, Ji P, Granberg KJ, Bernard B, Hu L, Cogdell DE, Zhou X, Yli-Harja O, Nykter M, Shmulevich I, Yung WK, Fuller GN, Zhang W (2015) Genomically amplified Akt3 activates DNA repair pathway and promotes glioma progression. Proc Natl Acad Sci USA 112:3421–3426. https://doi.org/10.1073/pnas.1414573112CrossRefPubMedPubMedCentral

34.

Etcheverry A, Aubry M, de Tayrac M, Vauleon E, Boniface R, Guenot F, Saikali S, Hamlat A, Riffaud L, Menei P, Quillien V, Mosser J (2010) DNA methylation in glioblastoma: impact on gene expression and clinical outcome. BMC Genomics 11:701. https://doi.org/10.1186/1471-2164-11-701CrossRefPubMedPubMedCentral

35.

Shinawi T, Hill VK, Krex D, Schackert G, Gentle D, Morris MR, Wei W, Cruickshank G, Maher ER, Latif F (2013) DNA methylation profiles of long- and short-term glioblastoma survivors. Epigenetics 8:149–156. https://doi.org/10.4161/epi.23398CrossRefPubMedPubMedCentral

36.

LeBlanc VG, Marra MA (2016) DNA methylation in adult diffuse gliomas. Brief Funct Genomics 15:491–500. https://doi.org/10.1093/bfgp/elw019CrossRefPubMed

37.

Bartke T, Vermeulen M, Xhemalce B, Robson SC, Mann M, Kouzarides T (2010) Nucleosome-interacting proteins regulated by DNA and histone methylation. Cell 143:470–484. https://doi.org/10.1016/j.cell.2010.10.012CrossRefPubMedPubMedCentral

38.

Lindroth AM, Park YJ, McLean CM, Dokshin GA, Persson JM, Herman H, Pasini D, Miro X, Donohoe ME, Lee JT, Helin K, Soloway PD (2008) Antagonism between DNA and H3K27 methylation at the imprinted Rasgrf1 locus. PLoS Genet 4:e1000145. https://doi.org/10.1371/journal.pgen.1000145CrossRefPubMedPubMedCentral

39.

Yuan J, Zhang N, Zheng Y, Chen YD, Liu J, Yang M (2018) LncRNA GAS5 indel genetic polymorphism contributes to glioma risk through interfering binding of transcriptional factor TFAP2A. DNA Cell Biol 37:750–757. https://doi.org/10.1089/dna.2018.4215CrossRefPubMed

40.

Yang H, Zheng W, Shuai X, Chang RM, Yu L, Fang F, Yang LY (2015) MicroRNA-424 inhibits Akt3/E2F3 axis and tumor growth in hepatocellular carcinoma. Oncotarget 6:27736–27750. https://doi.org/10.18632/oncotarget.4811CrossRefPubMedPubMedCentral

41.

Lu C, Wang H, Chen S, Yang R, Li H, Zhang G (2018) Baicalein inhibits cell growth and increases cisplatin sensitivity of A549 and H460 cells via miR-424-3p and targeting PTEN/PI3K/Akt pathway. J Cell Mol Med 22:2478–2487. https://doi.org/10.1111/jcmm.13556CrossRefPubMedPubMedCentral

42.

Zhang H, Wang X, Chen Z, Wang W (2015) MicroRNA-424 suppresses estradiol-induced cell proliferation via targeting GPER in endometrial cancer cells. Cell Mol Biol (Noisy-le-grand) 61:96–101

43.

Zhao HF, Wang J, Shao W, Wu CP, Chen ZP, To ST, Li WP (2017) Recent advances in the use of PI3K inhibitors for glioblastoma multiforme: current preclinical and clinical development. Mol Cancer 16:100. https://doi.org/10.1186/s12943-017-0670-3CrossRefPubMedPubMedCentral

44.

Kaley TJ, Panageas KS, Mellinghoff IK, Nolan C, Gavrilovic IT, DeAngelis LM, Abrey LE, Holland EC, Lassman AB (2019) Phase II trial of an AKT inhibitor (perifosine) for recurrent glioblastoma. J Neurooncol 144:403–407. https://doi.org/10.1007/s11060-019-03243-7CrossRefPubMedPubMedCentral

Titel: Long non-coding RNA GAS5, by up-regulating PRC2 and targeting the promoter methylation of miR-424, suppresses multiple malignant phenotypes of glioma
verfasst von: Chen Jin
Jie Zhao
Zhi-Ping Zhang
Ming Wu
Jian Li
Ge-Lei Xiao
Bo Liu
Yu-Xiang Liao
Jing-Ping Liu
Publikationsdatum: 29.05.2020
Verlag: Springer US
Erschienen in: Journal of Neuro-Oncology / Ausgabe 3/2020
Print ISSN: 0167-594X
Elektronische ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-020-03544-2

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Akuter Schwindel: Wann lohnt sich eine MRT?

28.04.2024 Schwindel Nachrichten

Akuter Schwindel stellt oft eine diagnostische Herausforderung dar. Wie nützlich dabei eine MRT ist, hat eine Studie aus Finnland untersucht. Immerhin einer von sechs Patienten wurde mit akutem ischämischem Schlaganfall diagnostiziert.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Viel Bewegung in der Parkinsonforschung

25.04.2024 Parkinson-Krankheit Nachrichten

Neue arznei- und zellbasierte Ansätze, Frühdiagnose mit Bewegungssensoren, Rückenmarkstimulation gegen Gehblockaden – in der Parkinsonforschung tut sich einiges. Auf dem Deutschen Parkinsonkongress ging es auch viel um technische Innovationen.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2020

Potential differences between monolingual and bilingual patients in approach and outcome after awake brain surgery

Impact of neurosurgical enhanced recovery after surgery (ERAS) program on health-related quality of life in glioma patients: a secondary analysis of a randomized controlled trial

Global post-marketing safety surveillance of Tumor Treating Fields (TTFields) in patients with high-grade glioma in clinical practice

Diagnostic delay and outcome in immunocompetent patients with primary central nervous system lymphoma in Spain: a multicentric study

Early imaging marker of progressing glioblastoma: a window of opportunity